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Bevacizumab or Cetuximab adjusted by KRAS mutation status,
Wt or Mt. METHODS: We use the progression-free survival
(PFS) of the patients treated with FOLFIRI + Bevacizumab and
FOLFIRI + Cetuximab in mCRC taking in account the status of
KRAS, reported by Hecht and Van Cutsem at ASCO 2008. A
Markov-model was developed to evaluate the economic trend.
The cost of a clinical success (CS) was calculated, using the
needed number to treated (NNT) necessary for 12 months
patient free of progression (PFP) after the treatment had started
and the associated cost needed to obtaining that result. Only the
direct medical cost of First-line treatment was measured (the cost
included oncology drugs and other common drugs). RESULTS:
According with reported data for KRAS condition, PFS is
14.5/Wt and 11.9/Mt months with FOLFIRI + Bevacizumab and
9.9/Wt and 7.6/Mt months with FOLFIRI + Cetuximab. The
NNT to mantaining one patient in PFS is 1.47/Wt and 1.59/Mt
patients for FOLFIRI + Bevacizumab, and 1.75/Wt and 2.07/Mt
patients for FOLFIRI + Cetuximab. The expected cost at 12
months for FOLFIRI + Bevacizumab was US$4,980.81/Wt and
US$4,394.08/Mt. With FOLFIRI + Cetuximab: US$7,894.03/Wt
and US$6,663.18/Mt. Finally the cost of CS was
US$7,301.05/Wt and US$7,002.24/Mt with FOLFIRI +
Bevacizumab; and US$13,821.50/Wt and US$13,950.00/Mt
with FOLFIRI + Cetuximab. CONCLUSIONS: The use of
FOLFIRI + Bevacizumab achieves a longer PFS regardless KRAS
status, in comparison with the FOLFIRI + Cetuximab scheme.
Analyzing costs of clinical success and costs of general manage-
ment (expressed in 12 months period), the scheme based on
FOLFIRI + Bevacizumab has advantages on the other, either the
patients were K-RAS mutant and wild-type. This allow efﬁciency
because saves resources during the treatment for mCRC patients.
PCN34
PHARMAECONOMIC EVALUATION OFTHE USE OF
ERLOTINIB IN NON-SMALL CELLS LUNG CANCER (NSCLC)
WITH FAILURETO PREVIOUS CHEMOTHERAPY
Tenorio C1,Vargas J2, Pacheco MI3, González-Michaca L3
1Instituto Nacional de Cancerología, Mexico, DF, Mexico,
2Econopharma Consulting SA de CV, Mexico, DF, Mexico,
3Roche México, México, DF, Mexico
OBJECTIVES: To perform a cost-effectiveness evaluation, from
the provider perspective, of Erlotinib in the treatment of NSCLC
patients, who had failed to previous chemotherapy compared to
Docetaxel and Pemetrexed. METHODS: A literature review
about the efﬁcacy of Docetaxel, Pemetrexed and Erlotinib on the
NSCLC treatment with previous failure to chemotherapy was
done. Direct medical costs were expressed as 21 day cycles, it
included toxicity cost (fever, neutropenia, rash and diarrhea).
The economic evaluation was performed calculating the cost of
clinical success (CS). This cost was deﬁned as the required
number of patients treated (RPT) in order to achieve 1 progres-
sion free patient (PFP) or dead during the following 6 months
after the start of the treatment. RESULTS: The cost for 6 months
follow-up was USD$730.59 for Erlotinib, USD$7976.20 for
Docetaxel and USD$8031.09 for Pemetrexed. The RPT for Erlo-
tinib was lower than the RPT for Docetaxel and Pemetrexed,
(6.69, 9.13 y 8.42 patients respectively). The cost for achieving a
CS was USD$51,073.53, USD$72,853.27 and USD$67,596.08
respectively. The lower RPT to maintain one PFP at 6 months
with Erlotinib represents an institutional saving of
USD$21,779.74 vs. Docetaxel and USD$16,522.55 vs. Pemetr-
exed. CONCLUSIONS: Erlotinib is a more effective alternative
in achieving a longer progression-free survival than Docetaxel
and Pemetrexed in the Mexican context. The best hematologic
safety proﬁle of Erlotinib (lack of fever or neutropenia) offers an
additional cost reduction by less toxicity of the treatment. The
cost-effectiveness analysis shows that the use of Erlotinib is a
dominant therapy, since it consumes fewer resources to obtain a
CS. This savingss might enhance the public health expenditure
between 24% (vs Pemetrexed)–30% (vs Docetaxel).
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OBJECTIVES: For the ﬁrst time, the cost-effectiveness and cost-
utility of all feasible CHOP-based 2nd line chemotherapy regi-
mens for follicular non-Hodgin lymphoma (FL) were assessed.
Here, rituximab (R) was added to CHOP as induction and main-
tenance (RCHOP-R), as induction only (RCHOP) or not at all
(CHOP). METHODS: A Markov state-transition model based
on trial results (progression-free survival, PFS, and overall sur-
vival, OS) and literature (resource use, unit costs and utilities)
was used to perform the economic evaluation from the Finnish
health care payer perspective excluding productivity losses. PFS
and OS were extrapolated to the model from 2-year Kaplan-
Meier curves using Weibull survival functions with a conserva-
tive assumption of maximum 5-year treatment beneﬁt. The
impacts of various assumptions were assessed (discounting with
5% and 0%, time-horizon from the with-in trial of 4 years up to
30 years, and survival function form as Weibull and Log logistic)
in addition to probabilistic sensitivity analysis. Probabilistic sen-
sitivity analysis and multinomial cost-effectiveness acceptability
curves were established based on the second-order Monte Carlo
simulation (2000) results. RESULTS: The PFS, OS and quality-
adjusted survival in terms of quality-adjusted life-years (QALY)
were clinically signiﬁcantly higher for RCHOP-R than for the
comparators. The incremental cost-effectiveness ratios were
€26,862 per QALY gained for RCHOP-R vs. RCHOP, €23,574
for RCHOP-R vs. CHOP, and €20,767 for RCHOP vs. CHOP.
RCHOP-R was the most cost-effective option when the willing-
ness to pay (WTP) per QALY gained exceeded €26,934. Potential
cost-effectiveness for RCHOP-R was obtained with the WTP of
€27,445 and the probability of RCHOP-R’s cost-effectiveness
was 91% with the WTP value of €50,000 per QALY. The results
were robust against changes in discounting and time-horizon.
The use Log logistic survival function would have beneﬁtted
RCHOP-R. CONCLUSIONS: Rituximab induction and mainte-
nance together with CHOP as RCHOP-R is a potentially cost-
effective 2nd line treatment option for the FL.
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OBJECTIVES: According to the existing guidelines FAC and
CMF protocols for the treatment of early breast cancer are
equaly effective. The objective was to evaluate safety proﬁle and
pharmacoeconomic aspects of these two protocols, the study was
performed at Internal Oncology Clinic, Oncology Institute of
Vojvodina. METHODS: Two treatment protocols were used:
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CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2,
ﬂuorouracil 600 mg/m2) in 19 women or FAC (ﬂuorouracil
500 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/
m2) in 42 women. Alltogether 61 women were included into
study. Frequency and gradus of unwanted effects were measured
during ﬁve days after one arrival for the treatment. Neuthropenia
was measured by counting white blood cells 18–20 days after
chemotherapy. Diarrhoea, nausea and vomiting were graduated
by counting of number of episodes per day for ﬁve days after
each treatment. For each protocol the costs of treatment for
cytostatics as well as for treatment of unwanted effects and need
for prolonged hospitalisation were calculated. RESULTS: There
was a higher incidence of nausea, vomiting and neuthropenia in
FAC vs. CMF treatments (73.81%, 23.57%, 21.43% vs.
57.98%, 15.79%, 10.53%) and higher incidence of diarrhoea in
CMF vs. FAC treatments (5.68% vs. 2.38%). Anthracycline-
based protocols (FAC) caused greater severity of nausea, vomit-
ing and diarrhoea than CMF with equaly severe neuthropenia.
Drugs used for treatment of nausea, vomiting and neuthropenia
were setrons, corticosteroids and metoclopramide. The cost for
the one treatment episode for cytostatics were higher for FAC
(66.94 EU pre single dose, 401.64 EU for the whole cycle) than
for CMF (19,10 EU per single dose, 229.20 EU for whole cycle).
The costs of drugs used for the treatment of AEs were 13.20 EU/
patient/episode reciving CMF and 17.24 EU/patient/episode
reciving FAC protocol. CONCLUSIONS: CMF is safer and
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OBJECTIVES: The MA17 trial showed that addition of letrozole
after 5 years tamoxifen was effective in further reducing the risk
of relapse in women with breast cancer. Recent data also indicate
that the cost of breast cancer relapse is much higher than previ-
ously shown, which has important implications for the beneﬁt of
adjuvant treatment. Further, the cost-effectiveness of adjuvant
treatment from a societal perspective and in the Nordic countries
is so far not extensively assessed. The objective of this study was
to assess cost-effectiveness of extending the adjuvant therapy in
Sweden, from a societal perspective. METHODS: Consequences
for a woman at the age of 62 years who have completed 5 years
tamoxifen treatment were assessed, from a societal and health
care perspective. Clinical data on risk of relapse and adverse
events were based on the MA17 trial. Costs, health utilities and
survival data were based on recent detailed Swedish data. A
reduction in relapse risk was extrapolated into a survival beneﬁt,
by assuming a higher mortality for patients with relapse.
RESULTS: The total societal cost for letrozole- and placebo-
treated patients were €7700 and €6300, respectively, a difference
of €1500. The difference in life-years and QALYs were 0.23 and
0.18, respectively, leading to costs of €6500 per life-years gained
and €8300 per QALY gained. The corresponding cost-
effectiveness ratios from a health care perspective were €10,500
per life-years gained and €13,400 per QALY gained. CONCLU-
SIONS: The study indicates that the incremental cost per QALY
gained for extended letrozole treatment in Sweden is low, and
hence indicates that money spent of extending the adjuvant treat-
ment with letrozole probably is money well spent in Sweden.
More long-term data on the overall survival gain would be
valuable to further validate the assumption used in the analysis.
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OBJECTIVES: To predict the expected incremental costs and
mean life-years associated with adding bevacizumab to
FOLFOX4 in the adjuvant treatment of patients with AJCC/
UICC stage III colon carcinoma following surgical resection.
METHODS: A three-health state (disease-free survival [DFS],
relapse/new occurrence of colon carcinoma, and death) Markov
model was used to explore the effects of adding one year of
adjuvant treatment with bevacizumab to the existing adjuvant
FOLFOX4 treatment regimen. Baseline DFS for FOLFOX4-
treated patients was based on published data from the MOSAIC
trial (André et al 2004). The relative risk reduction for bevaci-
zumab was based on protocol assumptions for the ongoing phase
III AVANT study. Outcomes included life-years, QALYs, direct
costs, and incremental cost-effectiveness ratios (ICERs) expressed
as costs per QALY or life-year gained. A life time horizon (40
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